<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03251469</url>
  </required_header>
  <id_info>
    <org_study_id>2</org_study_id>
    <nct_id>NCT03251469</nct_id>
  </id_info>
  <brief_title>Single Dose of Tranexamic Acid and Blood Loss, in Elderly Patients With Hip Fracture</brief_title>
  <official_title>Single Dose of Tranexamic Acid at the Time of Surgery and Blood Loss, in Elderly Patients Undergoing Hip Fracture Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the hypothesis that single dose of tranexamic acid
      (TXA) preoperatively will lower blood loss and transfusion rate in elderly patients with hip
      fractures (intertrochanteric or Subcapital), that will be treated with intramedullary nailing
      and cemented hemiarthroplasty respectively. After application of inclusion and exclusion
      criteria, patients will be randomized in two groups. Group 1 will include patients that
      receive preoperatively single dose of TXA (15mg/kg) and Group 2 will include patients that
      receive normal saline (control group).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of transfusions of allogeneic RBC from surgery up to day 4</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>total blood loss from surgery to day</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of vascular events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <condition>Hip Fractures</condition>
  <condition>Complication, Postoperative</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous tranexamic acid, 15mg/kg, preoperatively, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous normal saline, 100mg, preoperatively, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid 15mg/kg , iv, Single Dose</intervention_name>
    <description>Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline, 100mg, iv, Singe dose</intervention_name>
    <description>Normal Saline, 100mg, administered intravenously, preoperatively in single dose</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive elderly patients (age &gt;75 yo) undergoing hip fracture surgery for a stable
             or unstable intertrochanteric hip fracture with the insertion of a short
             intramedullary nail (IMN) as well as patients treated surgically with cemented
             hemiarthroplasty for acute femoral neck (subcapital) hip fracture.

        Exclusion Criteria:

          -  Any contraindication for tranexamic acid

          -  Multiple fractures

          -  Requirement for anticoagulant therapy that could not be stopped.

          -  Ongoing thromboembolic event

          -  reduced kidney function

          -  malignancy,

          -  pathological fracture

          -  previous operation on the affected hip

          -  Active coronary artery disease (event in the past 12 months).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vasileios S Nikolaou, MD</last_name>
    <phone>+306932543400</phone>
    <email>vassilios.nikolaou@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Department of Orthopaedics</name>
      <address>
        <city>Athens</city>
        <state>Attika</state>
        <zip>14233</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasileios Nikolaou, MD</last_name>
      <phone>+306932543400</phone>
      <email>vassilios.nikolaou@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2017</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Vasileios S. Nikolaou</investigator_full_name>
    <investigator_title>Assistant Professor of Orthopaedics</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>blood tranfusion</keyword>
  <keyword>hip fractures</keyword>
  <keyword>elderly</keyword>
  <keyword>blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

